BriaCell Therapeutics (TSE:BCT) has released an update.
BriaCell Therapeutics Corp. has reported progress in its investigation into illegal trading of its stocks, revealing significant imbalances in settlement shares after consulting with prime brokers and has lodged formal complaints with financial regulatory authorities in the U.S. and Canada. The company, which specializes in developing innovative immunotherapies for cancer treatment, is actively collaborating with regulatory bodies to address these manipulative trading practices and pledges to keep the public informed on developments.
For further insights into TSE:BCT stock, check out TipRanks’ Stock Analysis page.
